Inhibitory effect of Xinlikang capsules on the proliferation of hematological tumor cells
Objective To determine the possible application of Xinlikang capsules for hematological tumors.Methods MTS assay was used to detect the inhibitory effect of Xinlikang capsule on the proliferation of 8 strains of human hematological tumor cells.Flow cytometry was used to detect the effect of Xinlikang capsules on the cell cycle arrest and apoptosis promotion of acute myeloid leukemia MV-4-11 cells.The protein levels of pro-Caspase 3,cleaved-Caspase 3 and NF-κB p65 in MV-4-11 cells were detected by Western blot.Based on the mice loaded with MV-4-11 subcutaneous tumor transplantation,the effect of Xinlikang capsules on the tumor growth was studied.Results The IC50 values of Xinlikang capsules on MV-4-11,RS4;11,MM.1S,RPMI-8226,Mino,Jeko-1,OCI-LY10 and TMD8 were(54.05±6.33),(125.33±2.46),(655.87±7.95),(153.33±8.50),(188.70±9.11),(180.87±7.31),(186.10±6.55)and(253.53±8.88)µg·mL-1.Xinlikang capsules promoted the apoptosis of MV-4-11 cells in a concentration-dependent manner.When the concentration reached 500 µg·mL-1,the apoptosis rate was(99.41±0.36)%(P＜0.001),but the effect on cell cycle was weak.Xinlikang capsules promoted the cleavage of pro-Caspase 3 and down-regulate NF-κB p65 in MV-4-11 cells in a concentration-dependent manner.The clinical drug concentration(1000 mg·kg-1)of Xinlikang capsules significantly inhibited the tumor growth of mice loaded with MV-4-11 subcutaneous tumor transplantation,with the inhibition rate of 57.28%.Conclusion Xinlikang capsules can inhibit the proliferation of 8 hematological tumor cell lines.The proliferation inhibition on human acute myeloid leukemia MV-4-11 cells mainly caused by inhibiting the NF-κB pathway and promoting the cell apoptosis.The clinical concentration of Xinlikang capsules may well inhibit the tumor growth of mice loaded with MV-4-11 subcutaneous tumor transplantation,suggesting Xinlikang capsules may be used as an adjuvant therapy for hematologic malignancies.
NETL
NSTL
万方数据
